Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 6, 2010, Pages 2588-2595

  Cabanillas, Maria E ^a,b   Waguespack, Steven G ^a   Bronstein, Yulia ^a   Williams, Michelle D ^a   Feng, Lei ^a   Hernandez, Mike ^a   Lopez, Adriana ^a   Sherman, Steven I ^a   Busaidy, Naifa L ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CALCIUM; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB; THYROGLOBULIN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; BONE METASTASIS; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE COURSE; FATIGUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LUNG DISEASE; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIODIAGNOSIS; SIDE EFFECT; SKIN MANIFESTATION; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TISSUE SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; WEIGHT REDUCTION; BLOOD; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OFF LABEL DRUG USE; PATHOLOGY; RADIOGRAPHY; SURVIVAL; THYROID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; INDOLES; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OFF-LABEL USE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRROLES; SURVIVAL ANALYSIS; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77954476036     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1923     Document Type: Article

References (34)

1. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, Minuto M, Guastalli M, Miccoli P 2008 Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother 62:559-563
2. Shaha AR, Shah JP, Loree TR 1996 Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 172:692-694
3. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229-1242
4. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW 2007 Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 110:1451-1456
5. Shaha AR, Shah JP, Loree TR 1997 Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 174:474-476
6. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899
7. Sherman SI 2008 Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 37:511-524, xi
8. Lin JD, Chao TC 2005 Vascular endothelial growth factor in thyroid cancers. Cancer Biother Radiopharm 20:648-661 (Pubitemid 43099615)
9. Tuttle RM, Fleisher M, Francis GL, Robbins RJ 2002 Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87:1737-1742
10. Vieira JM, Santos SC, Espadinha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S, Leite V 2005 Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol 153:701-709
11. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627
12. Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM, Clayman GL 2009 High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 15:485-491
13. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RASBRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457
14. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
15. Schwartz GK, Robertson S, Shen A, Wang E, Pace L, Dials H, Mendelson D, Shannon P, Gordon M 2009 A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J Clin Oncol Vol. 27, no. 15S, Abstract 3513
16. Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, Rischin D 2008 Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 19:547-552
17. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
18. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
19. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42
20. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH 2002 ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-5754
21. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P 2009 Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol Vol. 27, no. 15S, Abstract 9000
22. Sherman SI, Tuttle RM, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Doherty GM, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ 2009 NCCN practice guidelines in oncology: thyroid carcinoma. J Natl Compr Canc Netw 1.2009
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
24. Lee JJ, Tu ZN 1997 A versatile one-dimensional distribution plot: the BLiP plot. The American Statistician 51:353-358 (Pubitemid 127153106)
25. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, Nistal M, Santisteban P 2006 The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 13:257-269
26. Jo YS, Li S, Song JH, Kwon KH, Lee JC, RhaSY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667-3670
27. Cohen EE, Needle BM, Cullen KJ, Wong SJ, Wade JL, Ivy SP, Villaflor VM, Seiwert TY, Nichols K, Vokes EE 2008 Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol Vol. 26, no. 15S, Abstract 6025
28. Package insert 2010 Sunitinib (Sutent). New York: Pfizer Inc.
29. Package insert 2009 Sorafenib (Nexavar). Emeryville, CA: Bayer Health Care and Onyx Pharmaceuticals Inc.
30. Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, Aractingi S, Grange JD, Poirier-Colame V, Malka D, Soria JC, Mateus C, Robert C 2009 Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 27:e59-61
31. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM 2009 Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7:20-23
32. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R 2008 Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 144:779-782
33. Kong HH, Turner ML 2009 Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol 61:360-361
34. Kong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML 2007 Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 56:171-172